Journal of Cardiac Failure
Volume 17, Issue 4 , Pages 265-271 , April 2011

Response to Inhaled Nitric Oxide Predicts Survival in Patients With Pulmonary Hypertension

  • Richard A. Krasuski, MD

      Affiliations

    • Director of Adult Congenital Heart Disease Service, Division of Cardiovascular Medicine, Cleveland Clinic Foundation, Cleveland, OH
    • Corresponding Author InformationReprint requests: Richard A. Krasuski, MD, Desk J2-4, Cardiovascular Medicine, Cleveland Clinic Foundation, 9500 Euclid Ave, Cleveland, OH 44195. Tel: (210) 445-7433; Fax: (210) 445-6163.
    • ,
  • Ganesh P. Devendra, BA

      Affiliations

    • Cleveland Clinic Lerner College of Medicine of Case Western Reserve University, Cleveland, OH
    • ,
  • Stephen A. Hart, BS

      Affiliations

    • Cleveland Clinic Lerner College of Medicine of Case Western Reserve University, Cleveland, OH
    • ,
  • Andrew Wang, MD

      Affiliations

    • Division of Cardiology, Department of Medicine, Duke University Medical Center, Durham, NC
    • ,
  • J. Kevin Harrison, MD

      Affiliations

    • Division of Cardiology, Department of Medicine, DukeUniversity Medical Center, Durham, NC
    • ,
  • Thomas M. Bashore, MD

      Affiliations

    • Division of Cardiology, Department of Medicine, DukeUniversity Medical Center, Durham, NC

Received 29 September 2010 ,Revised 18 November 2010 ,Accepted 22 November 2010.

References 

  1. Budhiraja R, Tuder RM, Hassoun PM. Endothelial dysfunction in pulmonary hypertension. Circulation. 2004;109:159–165
  2. Cella G, Bellotto F, Tona F, et al. Plasma markers of endothelial dysfunction in pulmonary hypertension. Chest. 2001;120:1226–1230
  3. Farber HW, Loscalzo J. Pulmonary arterial hypertension. New Engl J Med. 2004;351:1655–1665
  4. Rich S, Dantzker DR, Ayres SM, et al. Primary pulmonary hypertension. A national prospective study. Ann Intern Med. 1987;107:216–223
  5. Barst RJ, Rubin LJ, Long WA, et al. A comparison of continuous intravenous epoprostenol (prostacyclin) with conventional therapy for primary pulmonary hypertension. The Primary Pulmonary Hypertension Study Group. New Engl J Med. 1996;334:296–302
  6. McLaughlin VV, Genthner DE, Panella MM, Rich S. Reduction in pulmonary vascular resistance with long-term epoprostenol (prostacyclin) therapy in primary pulmonary hypertension. New Engl J Med. 1998;338:273–277
  7. Olschewski H, Simonneau G, Galie N, et al. Inhaled iloprost for severe pulmonary hypertension. New Engl J Med. 2002;347:322–329
  8. McLaughlin VV, Sitbon O, Badesch DB, et al. Survival with first-line bosentan in patients with primary pulmonary hypertension. Eur Resp J. 2005;25:244–249
  9. Rubin LJ, Badesch DB, Barst RJ, et al. Bosentan therapy for pulmonary arterial hypertension. New Engl J Med. 2002;346:896–903
  10. McLaughlin VV, Gaine SP, Barst RJ, et al. Efficacy and safety of treprostinil: an epoprostenol analog for primary pulmonary hypertension. J Cardiovasc Pharmacol. 2003;41:293–299
  11. Channick RN, Simonneau G, Sitbon O, et al. Effects of the dual endothelin-receptor antagonist bosentan in patients with pulmonary hypertension: a randomised placebo-controlled study. Lancet. 2001;358:1119–1123
  12. Liu C, Cheng J. Endothelin receptor antagonists for pulmonary arterial hypertension. Cochrane Database Systemic Ref. 2005;(1):CD004434
  13. Skoro-Sajer N, Lang I. The role of treprostinil in the management of pulmonary hypertension. Am J Cardiovasc Drugs. 2008;8:213–217
  14. Sastry BK, Narasimhan C, Reddy NK, Raju BS. Clinical efficacy of sildenafil in primary pulmonary hypertension: a randomized, placebo-controlled, double-blind, crossover study. J Am Coll Cardiol. 2004;43:1149–1153
  15. Singh TP, Rohit M, Grover A, Malhotra S, Vijayvergiya R. A randomized, placebo-controlled, double-blind, crossover study to evaluate the efficacy of oral sildenafil therapy in severe pulmonary artery hypertension. Am Heart J. 2006;151:851.e851–851.e855
  16. Benedict N, Seybert A, Mathier MA. Evidence-based pharmacologic management of pulmonary arterial hypertension. Clin Therapeutics. 2007;29:2134–2153
  17. Nagaya N. Drug therapy of primary pulmonary hypertension. Am J Cardiovasc Drugs. 2004;4:75–85
  18. Atwood CW, McCrory D, Garcia JG, Abman SH, Ahearn GS. American College of Chest Physicians. Pulmonary artery hypertension and sleep-disordered breathing: ACCP evidence-based clinical practice guidelines. Chest. 2004;126:72Se7S
  19. Badesch DB, Abman SH, Ahearn GS, et al. Medical therapy for pulmonary arterial hypertension: ACCP evidence-based clinical practice guidelines. Chest. 2004;126:35S–62S
  20. Rich S, Kaufmann E, Levy PS. The effect of high doses of calcium-channel blockers on survival in primary pulmonary hypertension. New Engl J Med. 1992;327:76–81
  21. Simonneau G, Galie N, Rubin LJ, et al. Clinical classification of pulmonary hypertension. J Am Coll Cardiol. 2004;43:5S–12S
  22. Simonneau G, Robbins IM, Beghetti M, et al. Updated clinical classification of pulmonary hypertension. J Am Coll Cardiol. 2009;54:S43–S54
  23. Post MC, Janssens S, Van de Werf F, Budts W. Responsiveness to inhaled nitric oxide is a predictor for mid-term survival in adult patients with congenital heart defects and pulmonary arterial hypertension. Eur Heart J. 2004;25:1651–1656
  24. Ulrich S, Fischler M, Speich R, Popov V, Maggiorini M. Chronic thromboembolic and pulmonary arterial hypertension share acute vasoreactivity properties. Chest. 2006;130:841–846
  25. Sitbon O, Humbert M, Jais X, et al. Long-term response to calcium channel blockers in idiopathic pulmonary arterial hypertension. Circulation. 2005;111:3105–3111
  26. Leuchte HH, Schwaiblmair M, Baumgartner RA, Neurohr CF, Kolbe T, Behr J. Hemodynamic response to sildenafil, nitric oxide, and iloprost in primary pulmonary hypertension. Chest. 2004;125:580–586
  27. Morales-Blanhir J, Santos S, de Jover L, et al. Clinical value of vasodilator test with inhaled nitric oxide for predicting long-term response to oral vasodilators in pulmonary hypertension. Respir Med. 2004;98:225–234
  28. Raffy O, Azarian R, Brenot F, et al. Clinical significance of the pulmonary vasodilator response during short-term infusion of prostacyclin in primary pulmonary hypertension. Circulation. 1996;93:484–488
  29. Ricciardi MJ, Knight BP, Martinez FJ, Rubenfire M. Inhaled nitric oxide in primary pulmonary hypertension: a safe and effective agent for predicting response to nifedipine. J Am Coll Cardiol. 1998;32:1068–1073
  30. Roberts DH, Lepore JJ, Maroo A, Semigran MJ, Ginns LC. Oxygen therapy improves cardiac index and pulmonary vascular resistance in patients with pulmonary hypertension. Chest. 2001;120:1547–1555
  31. Sitbon O, Brenot F, Denjean A, et al. Inhaled nitric oxide as a screening vasodilator agent in primary pulmonary hypertension. A dose-response study and comparison with prostacyclin. Am J Resp Crit Care Med. 1995;151:384–389
  32. Sitbon O, Humbert M, Jagot JL, et al. Inhaled nitric oxide as a screening agent for safely identifying responders to oral calcium-channel blockers in primary pulmonary hypertension. The Eur Resp J. 1998;12:265–270
  33. Ghofrani HA, Wilkins MW, Rich S. Uncertainties in the diagnosis and treatment of pulmonary arterial hypertension. Circulation. 2008;118:1195–1201
  34. Skoro-Sajer N, Hack N, Sadushi-Kolici R, et al. Pulmonary vascular reactivity and prognosis in patients with chronic thromboembolic pulmonary hypertension: a pilot study. Circulation. 2009;119:298–305
  35. Archer SL, Michelakis ED. An evidence-based approach to the management of pulmonary arterial hypertension. Curr Opin Cardiol. 2006;21:385–392
  36. Barst RJ, McGoon M, Torbicki A, et al. Diagnosis and differential assessment of pulmonary arterial hypertension. J Am Coll Cardiol. 2004;43:40S–47S
  37. Krasuski RA, Warner JJ, Wang A, Harrison JK, Tapson VF, Bashore TM. Inhaled nitric oxide selectively dilates pulmonary vasculature in adult patients with pulmonary hypertension, irrespective of etiology. J Am Coll Cardiol. 2000;36:2204–2211
  38. Pepke-Zaba J, Higenbottam TW, Dinh-Xuan AT, Stone D, Wallwork J. Inhaled nitric oxide as a cause of selective pulmonary vasodilatation in pulmonary hypertension. Lancet. 1991;338:1173–1174
  39. Wessel DL, Adatia I, Thompson JE, Hickey PR. Delivery and monitoring of inhaled nitric oxide in patients with pulmonary hypertension. Crit Care Medi. 1994;22:930–938
  40. Oudiz RJ, Galie N, Olschewski H, et al. Long-term ambrisentan therapy for the treatment of pulmonary arterial hypertension. J Am Coll Cardiol. 2009;54:1971–1981
  41. Chen YF, Jowett S, Barton P, et al. Clinical and cost-effectiveness of epoprostenol, iloprost, bosentan, sitaxentan and sildenafil for pulmonary arterial hypertension within their licensed indications: a systematic review and economic evaluation. Health Technol Assess. 2009;13:1–320
  42. Galie N, Rubin L, Hoeper M, et al. Treatment of patients with mildly symptomatic pulmonary arterial hypertension with bosentan (EARLY study): a double-blind, randomised controlled trial. Lancet. 2008;371:2093–2100
  43. Montani D, Chaumais MC, Savale L, et al. Phosphodiesterase type 5 inhibitors in pulmonary arterial hypertension. Adv Ther. 2009;26:813–825
  44. Archer SL, Michelakis ED. Phosphodiesterase type 5 inhibitors for pulmonary arterial hypertension. N Engl J Med. 2009;361:1864–1871
  45. Jing ZC, Jiang X, Wu BX, et al. Vardenafil treatment for patients with pulmonary arterial hypertension: a multicentre, open-label study. Heart. 2009;95:1531–1536
  46. Barst RJ, Gibbs JS, Ghofrani HA, et al. Updated evidence-based treatment algorithm in pulmonary arterial hypertension. J Am Coll Cardiol. 2009;54:S78–S84
  47. Simonneau G, Rubin LJ, Galie N, et al. Addition of sildenafil to long-term intravenous epoprostenol therapy in patients with pulmonary arterial hypertension: a randomized trial. Ann Intern Med. 2008;149:521–530
  48. Taichman DB. Therapy for pulmonary arterial hypertension: the more, the merrier?. Ann Intern Med. 2008;149:583–585
  49. Galie N, Manes A, Negro L, Palazzini M, Bacchi-Reggiani ML, Branzi A. A meta-analysis of randomized controlled trials in pulmonary arterial hypertension. Eur Heart J. 2009;30:394–403

 See page 270 for disclosure information.

PII: S1071-9164(10)01230-3

doi: 10.1016/j.cardfail.2010.11.010

Journal of Cardiac Failure
Volume 17, Issue 4 , Pages 265-271 , April 2011

Article Tools

* Image Usage & Resolution